Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
- Author
- ROSS, Joseph S1 ; MADIGAN, David2 ; HILL, Kevin P3 ; EGILMAN, David S4 ; YONGFEI WANG5 ; KRUMHOLZ, Harlan M5 6
[1] Department of Geriatrics and Palliative Medicine, Mount Sinai School of Medicine, New York, New York, United States
[2] Department of Statistics, Columbia University, New York, United States
[3] Department of Psychiatry, Harvard Medical School, and McLean Hospital, Boston, Massachusetts, United States
[4] Department of Community Health, Brown University, Providence, Rhode Islands, United States
[5] Yale-New Haven Hospital Center for Outcomes Research and Evaluation and Section of Cardiovascular Medicine, United States
[6] Robert Wood Johnson Clinical Scholars Program, Department of Medicine and Section of Health Policy and Administration, School of Public Health (Dr Krumholz), Yale University School of Medicine, New Haven, Connecticut, United States - Source
Archives of internal medicine (1960). 2009, Vol 169, Num 21, pp 1976-1985, 10 p ; ref : 44 ref
- CODEN
- AIMDAP
- ISSN
- 0003-9926
- Scientific domain
- General medicine general surgery
- Publisher
- American Medical Association, Chicago, IL
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Antiinflammatoire non stéroïde Donnée médicale Essai clinique Médecine Médicament Placebo Pool Rofécoxib Surveillance Sécurité Toxicité Enzyme Inhibiteur cyclooxygenase 2 Inhibiteur enzyme Oxidoreductases Prostaglandin-endoperoxide synthase
- Keyword (en)
- Non steroidal antiinflammatory agent Medical data Clinical trial Medicine Drug Placebo Pool Rofecoxib Surveillance Safety Toxicity Enzyme Cyclooxygenase 2 inhibitor Enzyme inhibitor Oxidoreductases Prostaglandin-endoperoxide synthase
- Keyword (es)
- Antiinflamatorio no esteroide Datos Médicos Ensayo clínico Medicina Medicamento Placebo Pool Rofecoxib Vigilancia Seguridad Toxicidad Enzima Inhibidor cyclooxygenase 2 Inhibidor enzima Oxidoreductases Prostaglandin-endoperoxide synthase
- Classification
- Discipline
- Generalities in medical sciences
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 22120449
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1001/archinternmed.2009.394 
https://dx.doi.org/10.1001/archinternmed.2009.394
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:30:\"10.1001\/archinternmed.2009.394\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:126:\"Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Archives of internal medicine (1960)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Arch. intern. med. (1960)\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:3:\"169\";s:8:\"\u0000*\u0000issue\";s:2:\"21\";s:8:\"\u0000*\u0000spage\";s:4:\"1976\";s:8:\"\u0000*\u0000epage\";s:4:\"1985\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-9926\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ROSS\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:14:\"MADIGAN, David\";i:1;s:13:\"HILL, Kevin P\";i:2;s:16:\"EGILMAN, David S\";i:3;s:12:\"YONGFEI WANG\";i:4;s:18:\"KRUMHOLZ, Harlan M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"AIMDAP\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:126:\"Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:28:\"American Medical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:30:\"10.1001\/archinternmed.2009.394\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:126:\"Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Archives of internal medicine (1960)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Arch. intern. med. (1960)\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:3:\"169\";s:8:\"\u0000*\u0000issue\";s:2:\"21\";s:8:\"\u0000*\u0000spage\";s:4:\"1976\";s:8:\"\u0000*\u0000epage\";s:4:\"1985\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-9926\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ROSS\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:14:\"MADIGAN, David\";i:1;s:13:\"HILL, Kevin P\";i:2;s:16:\"EGILMAN, David S\";i:3;s:12:\"YONGFEI WANG\";i:4;s:18:\"KRUMHOLZ, Harlan M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"AIMDAP\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:126:\"Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:28:\"American Medical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:30:\"10.1001\/archinternmed.2009.394\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:30:\"10.1001\/archinternmed.2009.394\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:126:\"Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Archives of internal medicine (1960)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Arch. intern. med. (1960)\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:3:\"169\";s:8:\"\u0000*\u0000issue\";s:2:\"21\";s:8:\"\u0000*\u0000spage\";s:4:\"1976\";s:8:\"\u0000*\u0000epage\";s:4:\"1985\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-9926\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ROSS\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:14:\"MADIGAN, David\";i:1;s:13:\"HILL, Kevin P\";i:2;s:16:\"EGILMAN, David S\";i:3;s:12:\"YONGFEI WANG\";i:4;s:18:\"KRUMHOLZ, Harlan M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"AIMDAP\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:126:\"Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:28:\"American Medical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:30:\"10.1001\/archinternmed.2009.394\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:126:\"Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Archives of internal medicine (1960)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Arch. intern. med. (1960)\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:3:\"169\";s:8:\"\u0000*\u0000issue\";s:2:\"21\";s:8:\"\u0000*\u0000spage\";s:4:\"1976\";s:8:\"\u0000*\u0000epage\";s:4:\"1985\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-9926\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ROSS\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:14:\"MADIGAN, David\";i:1;s:13:\"HILL, Kevin P\";i:2;s:16:\"EGILMAN, David S\";i:3;s:12:\"YONGFEI WANG\";i:4;s:18:\"KRUMHOLZ, Harlan M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"AIMDAP\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:126:\"Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:28:\"American Medical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:30:\"10.1001\/archinternmed.2009.394\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:126:\"Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Archives of internal medicine (1960)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Arch. intern. med. (1960)\";s:7:\"\u0000*\u0000date\";s:4:\"2009\";s:9:\"\u0000*\u0000volume\";s:3:\"169\";s:8:\"\u0000*\u0000issue\";s:2:\"21\";s:8:\"\u0000*\u0000spage\";s:4:\"1976\";s:8:\"\u0000*\u0000epage\";s:4:\"1985\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0003-9926\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ROSS\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Joseph S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:14:\"MADIGAN, David\";i:1;s:13:\"HILL, Kevin P\";i:2;s:16:\"EGILMAN, David S\";i:3;s:12:\"YONGFEI WANG\";i:4;s:18:\"KRUMHOLZ, Harlan M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"AIMDAP\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:126:\"Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance\";s:8:\"\u0000*\u0000place\";s:11:\"Chicago, IL\";s:6:\"\u0000*\u0000pub\";s:28:\"American Medical Association\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
